Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of violations of federal securities laws, encouraging affected investors to discuss their legal options before the January 9, 2026 deadline for lead plaintiff applications in a class action lawsuit [1][3]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates [3]. - It is claimed that the company overstated the quality of its supply chain and partners, leading to materially false statements about its business and operations [3]. - The lawsuit asserts that when the true details emerged, investors suffered damages due to the misleading information [3]. Group 2: Impact of Regulatory Actions - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, which caused the price of its American Depositary Shares (ADSs) to drop by over 13% in two trading sessions [4]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package, leading to a further decline of over 21% in ADS price over two trading sessions [5].
TLX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals